Strategic Pharma Partnerships AltPep's lead program SOBIN-AD targets soluble amyloid oligomers in Alzheimer's disease and has generated preclinical data showcased at AAIC and CTAD, signaling readiness for licensing or co-development discussions with pharma or biotech partners seeking early-disease-modifying assets. Opportunities include licensing SOBIN-AD rights, co-development arrangements, or sponsored research to accelerate IND-enabling studies, leveraging its alpha-sheet platform as a differentiator.

Diagnostics Collaboration AltPep also develops detection tools for amyloid diseases, creating a complementary path for diagnostic or biomarker companies. A joint venture or collaboration to co-develop companion diagnostics, patient stratification biomarkers, or monitoring assays could unlock cross-sell opportunities alongside therapeutic programs.

Preclinical Partnerships With ongoing preclinical data generation and active conference presentations, there is a strong opportunity to partner with CROs or academic labs to accelerate preclinical studies, scale up lead optimization, and prepare for IND-enabling work, shortening time-to-partner for potential license deals.

Credibility and Funding Recent governance moves and funding signals — board appointment from Matrix Capital and strategic hires — enhance credibility with investors and potential strategic partners, providing a gateway for co-development funding, syndicated deals, or strategic investments tied to milestone-based collaborations.

Geographic Strategy Headquartered in Seattle with a US-focused footprint, AltPep can capitalize on West Coast biotech clusters and academic collaboratives to access early-stage deals, while exploring regional partnerships or licensing in Europe and Asia through strategic alliances with local biotech firms and CROs.